Fexofenadine
Fexofenadine, sold under the brand name Allegra among others, is an antihistamine pharmaceutical drug used in the treatment of allergy symptoms, such as hay fever and urticaria.
Clinical data | |
---|---|
Trade names | Allegra, others |
AHFS/Drugs.com | Monograph |
MedlinePlus | a697035 |
License data |
|
Pregnancy category |
|
Routes of administration | By mouth |
Drug class | Antihistamine; H1 receptor antagonist |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | 30–41% |
Protein binding | 60–70% |
Metabolism | Hepatic (≤5% of dose) |
Elimination half-life | 14.4 hours |
Excretion | Feces (~80%) and urine (~10%) as unchanged drug |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.228.648 |
Chemical and physical data | |
Formula | C32H39NO4 |
Molar mass | 501.667 g·mol−1 |
3D model (JSmol) | |
Chirality | Racemic mixture |
| |
| |
(what is this?) (verify) |
Therapeutically, fexofenadine is a selective peripheral H1 blocker. It is classified as a second-generation antihistamine because it is less able to pass the blood–brain barrier and cause sedation, compared to first-generation antihistamines.
It was patented in 1979 and came into medical use in 1996. It is on the World Health Organization's List of Essential Medicines. Fexofenadine has been manufactured in generic form since 2011. In 2021, it was the 262nd most commonly prescribed medication in the United States, with more than 1 million prescriptions.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.